Indian Drug Regulation Needs a VITAMIN
Indian Economy & Market|April 2023
The Indian pharmaceutical industry ranks third internationally in volume. India is a chief exporter of pharmaceuticals with more than 200 nations served by Indian pharma exports. India supplies more than 50% of Africa’s requirement for generics, around 40% of generic demand in the USA, and around 25% of all medicine in the UK. Although India is proud of being the ‘pharmacy of the world,’ it would be right to say that the drugs regulatory bodies and laws must take the spate of oft-warnings more seriously. In the recent past, India has been beaten by a few mega pharma worries. The world mostly depends on the Indian pharmaceutical industry. However, growing worries over quality and the absence of drug regulations policy lead to the query of whether India is dwindling in its role.
Shivanand Pandit
Indian Drug Regulation Needs a VITAMIN

# In February 2023, an Indian pharmaceutical company based in Chennai, Global Pharma Healthcare, deferred a line of eye-drop manufacture being distributed in the USA market after the nation’s health authorities warned that it could be adulterated with drug-resistant germs that have been related to statements of eternal vision damage and one death from bloodstream contamination.

# In December 2022, the Central Drugs Standard Control Organisation (CDSCO) instigated an investigation concerning the death of eighteen children in Uzbekistan supposedly connected to a cough syrup produced by an Indian firm Marion Biotech based in Uttar Pradesh.

# In October 2022, the World Health Organization (WHO) issued a medical produce warning. Four products from India-based Maiden Pharmaceuticals based in New Delhi were adulterated with intolerable volumes of diethylene glycol and ethylene glycol, both poisonous to human beings. 

Drug regulation and supervision, also known as Pharmacovigilance is imperative in ensuring the safety of medicines and safeguarding patients from harm. As per the law, the Central Drugs Standard Control Organisation (CDSCO) is the apex supervisory association. The CDSCO delegates the Drug Controller General of India (DCGI), the authority to act as the governing head. The DGCI must perform under the guidance of the Drug Technical Advisory Board (DTAB) and the Drug Consultative Committee (DCC). 

この記事は Indian Economy & Market の April 2023 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

この記事は Indian Economy & Market の April 2023 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。

INDIAN ECONOMY & MARKETのその他の記事すべて表示
Globalism, Freedom & Democracy Do Not Mix
Indian Economy & Market

Globalism, Freedom & Democracy Do Not Mix

The world today is packed with wealthy institutions and individuals that stand in revolt against the ideas of freedom and democracy. They do not like the idea of geographically constrained states with zones of juridical power.

time-read
6 分  |
November 2024
WORLD DEVELOPMENT REPORT 2024 THE MIDDLE-INCOME TRAP
Indian Economy & Market

WORLD DEVELOPMENT REPORT 2024 THE MIDDLE-INCOME TRAP

A World Bank report titled 'World Development Report 2024: The Middle-Income Trap' indicates that India may take up to 75 years to attain just a quarter of the United States' per capita income. The insights in the report provides a useful reality check for India's ambitious goals, such as becoming a developed economy by 2047 or reaching a $5 trillion economy within the next three years.

time-read
5 分  |
November 2024
IN CONVERSATION: "We are working with a Vision 2035. I'm sure within next 5 years we will be ranking among the Fortune 500 companies.”
Indian Economy & Market

IN CONVERSATION: "We are working with a Vision 2035. I'm sure within next 5 years we will be ranking among the Fortune 500 companies.”

Sudarshan Pharma Industries Ltd., led by its promoters, Mr. Hemal V. Mehta, a chemical engineer, and Mr. Sachin V. Mehta, has established a strong foundation in specialty chemicals and bulk drugs. Their relentless enthusiasm is visible when they speak. Indian Economy & Market reached out, to piece together the company's achievements and new initiatives in detail.

time-read
9 分  |
November 2024
Sudarshan Pharma Industries Ltd. A MULTIBAGGER IN MAKING
Indian Economy & Market

Sudarshan Pharma Industries Ltd. A MULTIBAGGER IN MAKING

Sudarshan Pharma Industries Ltd. operates across various sectors in both the pharmaceutical and chemical industries, with a focus on specialty chemicals and intermediates, which find applications in Indian Le pharmaceuticals, paints, food products, and adhesives.

time-read
3 分  |
November 2024
MUTUAL FUND LITE OR MF LIT PROMISING PROGRESS FOR INVESTORS
Indian Economy & Market

MUTUAL FUND LITE OR MF LIT PROMISING PROGRESS FOR INVESTORS

The SEBI has streamlined rules for passively managed schemes to have the impact of letting more players in the mutual fund ecosystem and offering diversified, low-risk investment options to retail investors. It would increase market liquidity and attract participation from old as well as new Asset Management Companies (AMCs). Shivanand Pandit feels that MF Lite is going to democratize investment opportunities in the Indian financial market.

time-read
5 分  |
November 2024
BRICS Member States Ready to Dethrone Dollar
Indian Economy & Market

BRICS Member States Ready to Dethrone Dollar

AS the US weaponises the dollar in the Russian and Iranian sanctions, there is increasing desire by other developing countries to seek alternative currencies for trade, investment, and reserves, as well as developing alternative multilateral clearance systems outside of SWIFT.

time-read
3 分  |
November 2024
7 BEST PHARMA COMPANIES
Indian Economy & Market

7 BEST PHARMA COMPANIES

The pharmaceutical industry in India is expected to reach $65 Bn by end of 2024 and to $130 Bn by 2030. India is a major exporter of Pharmaceuticals, with over 200+ countries served by Indian pharma exports. While Nifty's performance has been lackluster over the past month, several pharmaceutical stocks have shown resilience.

time-read
10+ 分  |
November 2024
NEW INVESTMENT PRODUCT CATEGORY IS SEBI'S LATEST MOVE COMMENDABLE?
Indian Economy & Market

NEW INVESTMENT PRODUCT CATEGORY IS SEBI'S LATEST MOVE COMMENDABLE?

The Securities and Exchange Board of India (SEBI) has introduced a consultation paper proposing a new investment product category aimed at addressing a specific market need. This proposed asset class would offer investment options that sit between mutual funds (MFS) and PMS, filling a gap and providing greater flexibility in portfolio management. The new investment vehicle is designed for investors who are prepared to take on riskier market positions but find PMS schemes or AIFs out of reach. SEBI after reviewing the feedback and finalizing the regulations through stakeholder discussions, may issue the final regulations.

time-read
5 分  |
August 2024
DECODING THE CHINA MYTH
Indian Economy & Market

DECODING THE CHINA MYTH

Myths die hard. Among these is the great myth that China's poised to take over the world. Here, James Rickards debunks that myth.

time-read
7 分  |
August 2024
What Is In Store For The Indian Economy?
Indian Economy & Market

What Is In Store For The Indian Economy?

Until the 2014 Lok Sabha elections, when the Bharatiya Janata Party secured 282 seats and Narendra Modi ascended to power, India experienced 21 years of coalition governments. A decade later, the BJP holds 240 seats in the Lok Sabha, and India is once again governed by a coalition. Fitch has indicated that coalition politics and a weakened mandate for the NDA could hinder the passage of ambitious reform legislation. It raises the question: Do coalition governments impede the economic reform agenda?

time-read
5 分  |
July 2024